Bruker (BRKR) Lowered to Buy at BidaskClub

BidaskClub lowered shares of Bruker (NASDAQ:BRKR) from a strong-buy rating to a buy rating in a report issued on Thursday.

BRKR has been the topic of several other reports. Zacks Investment Research raised Bruker from a hold rating to a buy rating and set a $37.00 price target on the stock in a research report on Wednesday, November 8th. Bank of America raised Bruker from an underperform rating to a neutral rating and set a $34.00 price target on the stock in a research report on Friday, November 3rd. Cowen reissued a hold rating and set a $29.00 price target on shares of Bruker in a research report on Friday, November 3rd. BTIG Research initiated coverage on Bruker in a research report on Friday, January 5th. They set a buy rating and a $42.00 price target on the stock. Finally, JPMorgan Chase & Co. upgraded Bruker from an underweight rating to a neutral rating and set a $28.00 price objective on the stock in a report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $32.38.

Bruker (BRKR) traded up $0.47 during trading on Thursday, reaching $34.97. The company had a trading volume of 564,310 shares, compared to its average volume of 412,789. The firm has a market cap of $5,440.04, a price-to-earnings ratio of 37.20, a PEG ratio of 2.63 and a beta of 1.12. The company has a quick ratio of 1.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.65. Bruker has a 12-month low of $21.83 and a 12-month high of $36.53.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The firm had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. Bruker had a return on equity of 25.83% and a net margin of 8.85%. Bruker’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 EPS. sell-side analysts anticipate that Bruker will post 1.19 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 22nd. Shareholders of record on Monday, December 4th were issued a dividend of $0.04 per share. The ex-dividend date was Friday, December 1st. This represents a $0.16 annualized dividend and a yield of 0.46%. Bruker’s dividend payout ratio is presently 17.02%.

Hedge funds have recently bought and sold shares of the business. Koch Industries Inc. increased its holdings in Bruker by 2,573.5% during the 2nd quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock worth $324,000 after purchasing an additional 322,252 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in Bruker by 186.3% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 16,478 shares of the medical research company’s stock worth $475,000 after purchasing an additional 10,723 shares during the last quarter. Verition Fund Management LLC increased its holdings in shares of Bruker by 95.6% in the 2nd quarter. Verition Fund Management LLC now owns 26,891 shares of the medical research company’s stock valued at $776,000 after acquiring an additional 13,140 shares during the last quarter. Stifel Financial Corp bought a new stake in shares of Bruker in the 2nd quarter valued at approximately $575,000. Finally, Teachers Advisors LLC increased its holdings in shares of Bruker by 65.8% in the 2nd quarter. Teachers Advisors LLC now owns 245,720 shares of the medical research company’s stock valued at $7,087,000 after acquiring an additional 97,491 shares during the last quarter. Institutional investors own 65.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/15/bruker-brkr-lowered-to-buy-at-bidaskclub.html.

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply